Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial

IMPORTANCE: Antiangiogenic drug combinations with anti–programmed cell death 1 protein and anti–programmed cell death 1 ligand 1 (PD-L1) agents are a novel treatment option for lung cancer. However, survival remains limited, and the activity of these combinations for tumors with high tumor mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Provencio, Mariano, Ortega, Ana Laura, Coves-Sarto, Juan, Calvo, Virginia, Marsé-Fabregat, Raquel, Dómine, Manuel, Guirado, María, Carcereny, Enric, Fernández, Natalia, Álvarez, Ruth, Blanco, Remei, León-Mateos, Luis, Sánchez-Torres, José Miguel, Sullivan, Ivana Gabriela, Cobo, Manuel, Sánchez-Hernández, Alfredo, Massuti, Bartomeu, Sierra-Rodero, Belen, Mártinez-Toledo, Cristina, Serna-Blasco, Roberto, Romero, Atocha, Cruz-Bermúdez, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856905/
https://www.ncbi.nlm.nih.gov/pubmed/36520426
http://dx.doi.org/10.1001/jamaoncol.2022.5959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856905/
https://www.ncbi.nlm.nih.gov/pubmed/36520426
http://dx.doi.org/10.1001/jamaoncol.2022.5959

Ejemplares similares